DV
Dividend Vision

NERV — Minerva Neurosciences Inc

Minerva Neurosciences Inc (NERV)

Total return is -90.5% over the past 12.1 years, 472.4 points behind SPY at 381.9%. Its deepest 1-year drawdown was 51.4%.

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases, with its lead candidate roluperidone currently in Phase 3 trials for negative symptoms of schizophrenia. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotech development rather than current income.

NERV key facts

Asset type
Stock
Asset class
Equity
Inception date
07/01/2014
Last close
$4.58
Market cap
$208,717,408
Average volume
340000.0
Beta
-0.179
Payout ratio
0.0
Forward P/E
11.2108
EPS
$-37.96